Evidence map›Paper›PMID 41774417›Full record

ArticlePigment cell & melanoma research2025

Epidermotropic Metastatic Melanoma Presenting as Eruptive Primary Melanomas.

Jennifer Strong, Mitchell J Winkie, Patrick Hallaert, Scott B Whitecar, Elaine S Keung, Daniel Neelon, Karen G Zeman, Michele M Gage, William C Schaffenburg, Meagan M Simpson and 1 more

Abstract readCase Reports
In one paragraph

Article in Pigment cell & melanoma research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jennifer StrongDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0009-0001-4453-3234
Mitchell J WinkieHarvard Medical School, Boston, Massachusetts, USA.
Patrick HallaertDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0009-0007-1998-1119
Scott B WhitecarDepartment of Dermatology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Elaine S KeungDepartment of Pathology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Daniel NeelonDepartment of Pathology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Karen G ZemanDepartment of Hematology/Oncology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Michele M GageDivision of Surgical Oncology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
William C SchaffenburgDepartment of Dermatology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.ORCID 0000-0001-6906-6890
Meagan M SimpsonDepartment of Dermatology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Isaac BrownellDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-0090-9914

Funding

Investigation of skin cancer and skin diseaseZIAAR041224 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI BROWNELL, ISAAC · 2022 to 2025
$1.0M
Intramural NIH HHS ZIA AR041224NIAMS NIH HHS ZIA AR041224
6 · The paper itself

Abstract

We report on the use of molecular profiling to diagnose epidermotropic metastatic melanoma (EMM) in a patient who presented with eruptive primary melanomas. On histopathology, the patient's metastatic lesions resembled superficial spreading melanomas and were indistinguishable from independent primary melanomas. The patient's presumed primary melanoma was a stage IIIB nodular melanoma. Despite treatment with adjuvant nivolumab, the patient continued to form new superficial spreading melanomas. Due to suspicion for EMM, commercial panel sequencing was performed on tissue from four tumors. Comparison of reported somatic variants revealed a mutational profile that was conserved across all four lesions, establishing a diagnosis of stage IV EMM. Considering the progressive disease on immunotherapy, treatment was transitioned to encorafenib plus binimetinib, resulting in regression of existing lesions and cessation of new skin lesion formation. Aside from micrometastatic sentinel lymph node deposits from the presumed primary melanoma, the patient had no evidence of non-cutaneous metastases. EMM should be considered as a diagnosis for multiple superficial spreading melanomas arising synchronously or in rapid succession. As EMM and primary melanomas are often histopathologically indistinguishable, next generation sequencing is a valuable tool to confirm clonality and provide a definitive diagnosis.

Indexed as

MelanomaSkin NeoplasmsDiagnosis, DifferentialFemaleHumansMaleMiddle AgedMutationNeoplasm Metastasiscutaneous metastasisepidermotropic metastasiseruptive nevimelanomamultiple primary melanomassequence variants

Identifiers

PMID41774417
PMCPMC12265876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.